Approximately 15‑25 % of untreated children with KD develop coronary aneurysms; early treatment with high‑dose intravenous immunoglobulin (IVIG) reduces this risk to less than 5 % (Mayo Clinic, 2023). The aneurysms can be small (<5 mm), medium (5‑8 mm), or large/giant (>8 mm), and the size influences the intensity of follow‑up and therapy.

Common Causes

While Kawasaki disease itself is the primary trigger for coronary aneurysms in children, other conditions can lead to similar aneurysmal changes. The table below lists the most frequent etiologies that clinicians consider when a coronary aneurysm is identified.

• 1. Kawasaki disease – the leading cause of acquired coronary aneurysms in children.
• 2. Congenital coronary artery anomalies – rare structural defects present at birth.
• 3. Familial hypercholesterolemia – severe lipid disorder causing early atherosclerosis.
• 4. Systemic inflammatory diseases (e.g., systemic lupus erythematosus, Takayasu arteritis).
• 5. Connective‑tissue disorders such as Marfan or Ehlers‑Danlos syndrome.
• 6. Infectious vasculitides – e.g., syphilis, hepatitis B/C, HIV.
• 7. Drug‑induced vasculitis – certain chemotherapeutic agents or cocaine.
• 8. Radiation‑induced arterial injury – rare after high‑dose chest irradiation.
• 9. Post‑cardiac catheterization injury – mechanical trauma can cause pseudo‑aneurysms.
• 10. Idiopathic giant coronary aneurysms – when no cause is identified.

Associated Symptoms

Coronary aneurysms themselves rarely cause symptoms in the acute phase; they are usually discovered during echocardiography for Kawasaki disease. However, as they enlarge or become thrombosed, the following clinical features may appear:

• Chest discomfort or tightness, especially during exertion.
• Shortness of breath (dyspnea) or rapid breathing (tachypnea).
• Palpitations or irregular heartbeats.
• Syncope (fainting) – a possible sign of reduced cardiac output.
• Signs of heart failure (edema, fatigue, poor feeding in infants).
• Sudden cardiac arrest – rare but catastrophic.
• Persistent fever, rash, red eyes, swollen lips or tongue (the classic Kawasaki triad) that may coexist in the acute disease phase.

When to See a Doctor

Because coronary aneurysms can be silent until a serious event occurs, the threshold for medical evaluation is low. Seek professional care promptly if you notice any of the following:

• Fever lasting >5 days in a child with conjunctival injection, oral mucosal changes, rash, extremity swelling, or lymphadenopathy.
• Chest pain, pressure, or tightness that does not resolve with rest.
• New or worsening shortness of breath, especially during activity.
• Palpitations, irregular heartbeat, or a rapid pulse (>120 bpm in children).
• Swelling of the ankles or abdomen, dark urine, or sudden weight gain (possible heart failure).
• Any sign of stroke or neurological deficit (possible embolic event from a clot).

Diagnosis

Diagnosing a coronary aneurysm related to Kawasaki disease involves a combination of clinical criteria, laboratory markers, and imaging studies.

Clinical criteria for Kawasaki disease

According to the American Heart Association (AHA), a diagnosis is made when a child has fever ≥5 days plus at least four of the five principal features:

• Bilaterally non‑exudative conjunctival injection.
• Oral mucosal changes (red cracked lips, strawberry tongue).
• Peripheral extremity changes (erythema, edema, desquamation).
• Polymorphous rash.
• Cervical lymphadenopathy (≥1.5 cm).

Laboratory tests

• Complete blood count – often shows neutrophilia and anemia.
• Elevated inflammatory markers: C‑reactive protein (CRP) > 3 mg/dL, erythrocyte sedimentation rate (ESR) > 40 mm/hr.
• Elevated liver enzymes, hypoalbuminemia, and sterile pyuria may be present.
• Serum electrolytes and cardiac enzymes (troponin, BNP) if myocarditis is suspected.

Imaging modalities

• Echocardiography – First‑line, bedside tool; can visualize proximal coronary segments, measure aneurysm diameter, and assess ventricular function.
• Cardiac CT angiography (CTA) – Provides detailed 3‑D anatomy, useful for medium‑to‑large aneurysms and surgical planning.
• Cardiac magnetic resonance imaging (CMR) – Evaluates myocardial viability and detects silent ischemia.
• Coronary angiography – Invasive, reserved for cases where intervention (e.g., stent placement) is considered.

Risk stratification

Based on aneurysm size and Z‑score (standard deviation from normal diameter for body surface area), patients are grouped into:

• Low risk – No aneurysm or Z‑score <2.5.
• Intermediate risk – Small aneurysm (Z‑score 2.5–5).
• High risk – Medium/large or giant aneurysm (Z‑score >5).

Treatment Options

Therapy aims to (1) stop the vasculitic process, (2) prevent aneurysm formation, and (3) reduce the risk of thrombosis or stenosis in existing aneurysms.

Acute phase therapy

• Intravenous immunoglobulin (IVIG) – 2 g/kg as a single infusion within the first 10 days of fever. Reduces aneurysm risk by ~80 % (NIH, 2022).
• Aspirin – High‑dose (80–100 mg/kg/day) until the patient is afebrile for 48 h, then low‑dose (3–5 mg/kg/day) for antiplatelet effect for 6–8 weeks or longer if aneurysms persist.
• Corticosteroids – Adjunctive therapy (e.g., methylprednisolone 30 mg/kg/day for 3 days) for IVIG‑resistant cases (about 10‑15 % of patients).
• Infliximab or other biologics – Considered in refractory disease when IVIG + steroids fail.

Long‑term management of coronary aneurysms

• Antiplatelet therapy – Low‑dose aspirin remains standard; many clinicians add clopidogrel for medium/large aneurysms.
• Anticoagulation – Warfarin (target INR 2.0–3.0) or direct oral anticoagulants (e.g., rivaroxaban) are recommended for giant aneurysms (>8 mm) to prevent clot formation.
• Beta‑blockers – May be prescribed to reduce myocardial oxygen demand in patients with ischemia.
• Statins – Though data are limited in children, some cardiologists use them for endothelial protection.
• Regular cardiac imaging – Echo every 1–2 weeks in the acute phase, then at 6 months, 1 year, and annually thereafter, or sooner if symptoms change.
• Surgical or percutaneous interventions – Indicated for giant aneurysms with stenosis or thrombosis. Options include coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) with stenting.

Home and lifestyle measures

• Maintain a heart‑healthy diet rich in fruits, vegetables, whole grains, and low in saturated fat.
• Encourage age‑appropriate physical activity; avoid high‑intensity sports if large aneurysms are present until cleared by a cardiologist.
• Stay hydrated and monitor for any new chest pain or shortness of breath during activity.
• Adhere strictly to medication schedules; use pill organizers or phone reminders.
• Keep a copy of your child’s cardiac report and medication list for emergency personnel.

Prevention Tips

True primary prevention of Kawasaki disease is not yet possible because the exact trigger is unknown. However, secondary prevention—reducing the likelihood of aneurysm formation—relies on early recognition and prompt therapy.

• Educate parents and caregivers about the classic Kawasaki signs (fever + 4/5 features).
• Seek pediatric evaluation within the first 5 days of fever if the rash, conjunctivitis, or oral changes appear.
• Ensure timely administration of IVIG and aspirin as per AHA guidelines.
• Follow up closely with a pediatric cardiologist even if the initial echo is normal; some aneurysms develop later.
• Control modifiable cardiovascular risk factors (avoid tobacco smoke exposure, manage obesity) to protect arterial health.

Emergency Warning Signs

If any of the following occurs, go to the nearest emergency department or call 911 immediately:

• Sudden, severe chest pain or pressure that does not improve with rest.
• Lost consciousness or fainting spells.
• Rapid, irregular heartbeat (palpitations) associated with dizziness.
• Shortness of breath that worsens quickly or at rest.
• Swelling of the legs, abdomen, or sudden weight gain suggesting heart failure.
• Stroke‑like symptoms (weakness, facial droop, speech difficulty) – possible embolic event.

Understanding Kawasaki disease–related coronary aneurysms helps families act quickly, reduces long‑term heart risk, and improves outcomes. Always keep regular appointments with a pediatric cardiology team and never hesitate to seek emergency care if warning signs appear.